| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 211.6 | 195.7 | 181.7 |
| Other income | 4.3 | 4.2 | 4.5 |
| Total income | 215.9 | 199.8 | 186.2 |
| Profit before exceptional items & tax | 37.0 | 41.2 | 38.2 |
| Exceptional items | 0.0 | 0.0 | 11.2 |
| Profit before tax | 37.0 | 41.2 | 49.5 |
| Net profit | 28.2 | 30.6 | 36.9 |
| Operating margin | 17.1% | 20.6% | 26.6% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -23.60% |
|---|---|
| Net profit, quarter on quarter | -7.80% |
| Revenue, year on year | +16.50% |
| Operating profit, year on year | -3.00% |
| Operating profit, quarter on quarter | -11.60% |
NSE results filing, NSE: RPGLIFE. Figures extracted from the filing.
RPG Life Sciences Ltd: key numbers
- Share price
- ₹3,003.80
- Market cap
- ₹4,968 Cr
- Revenue (annual)
- ₹707.5 Cr
- Net profit (annual)
- ₹115.2 Cr
- P/E (TTM)
- 41.5×Sector 48.7×
- Promoter holding
- 72.95%+0.00% QoQ
- FII holding
- 0.87%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from RPG Life Sciences Ltd
All →RPG Life Sciences Results Update
RPG Life Sciences reported Q2 FY27 revenue of ₹211.6 crore, growing 16.5%, and adjusted EBITDA of ₹50.1 crore. The API business integration continues to progress.
RPG Life Sciences Board Meeting Date
RPG Life Sciences Limited has scheduled a board meeting on October 29, 2026, to consider and approve its unaudited financial results for the quarter ending September 30, 2026.
RPG Life Sciences Other Announcement
This is the quarterly shareholding pattern filing for RPG Life Sciences Ltd for the quarter ended September 30, 2026.
RPG Life Sciences Capital Structure Change
Clarus Trust acquired 37,463 shares of RPG Life Sciences through an open market transaction. This acquisition increases the acquirer's total stake to 7.04%.
RPG Life Sciences Merger & Restructuring
RPG Life Sciences announced the amalgamation of its wholly-owned subsidiary, Actis Generics, into its other subsidiary, RPG Active Pharma Limited. No share exchange is involved.
RPG Life Sciences Acquisition
RPG Life Sciences completed its acquisition of the entire stake in Actis Generics Private Limited, making it a subsidiary of the company.